2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors

Group 1: Teladoc Health - Teladoc was a leader in telemedicine during the pandemic, providing consultations and services from home [2] - Initially, Teladoc experienced rapid revenue growth but faced significant net losses due to noncash impairment charges as pandemic-related demand waned [3] - The company appointed a new CEO, Charles Divita, and aims to improve services and expand internationally, with 93.9 million members in its integrated care segment [3][4] - Teladoc has a gross margin of about 70%, indicating potential for profitability if top-line growth and expense control are achieved [4][5] Group 2: Novavax - Novavax has signed a significant agreement with Sanofi for its COVID-19 vaccine, receiving an upfront payment of $500 million and potential milestone payments of $700 million [6] - The company is focusing on developing vaccines for influenza and a combined COVID/flu vaccine, with recent regulatory hurdles now resolved [7] - Novavax's market cap is $1.4 billion, and successful phase 3 studies for its vaccine candidates could lead to strong market performance [8]